ArticleJournal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent2025
Psychiatric Medications and QTc Prolongation in the Pediatric Population.
Article in Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various medications used to treat psychiatric conditions are associated with prolongation of the QTc interval, which can lead to Torsades de Pointes, a deadly arrhythmia. Despite evidence of QTc prolongation, clinicians increasingly use psychiatric drugs in the pediatric population. Guidelines for prescribing many of these medications in children do not currently exist. To safely prescribe QTc prolonging drugs, especially in children with preexisting cardiovascular conditions, psychiatric providers, primary care physicians and/or pediatricians should conduct a detailed personal and family medical history, medication record, physical examination, and lab work, if clinically indicated, to rule out potential risk factors. Pharmacist input should be sought, if available. If risk factors are present and pre-treatment assessments identify cardiac risk factors, an assessment by a cardiologist may be necessary. To enhance treatment safety and mitigate QTc prolongation risks associated with psychiatric drug use in children, a standardized approach for drug prescribing that takes patient risk factors into account is proposed.
Identifiers
41890603PMC13016577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.